Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
February 11, 2021

Coronavirus company news summary – Chugai publishes positive Phase III results of Covid-19 antibody drug – J&J teams up with Biological E on Covid-19 vaccines manufacturing

By Allie Nawrat

11 February 2021

Wockhardt has been granted a six-month extension to its contract with the UK Government to fill-finish Covid-19 vaccines. This expands the initial agreement from 18 to 24 months, meaning the contract will last until August 2022. Manufacturing is expected to take place at CP Pharmaceuticals, Wockhardt’s subsidiary based in  Wrexham, North Wales.

Indian pharmaceutical company Biological E is looking to contract manufacture approximately 600 million doses of Johnson and Johnson (J&J)’s Covid-19 vaccine each year, according to Reuters. Biological E’s managing director Mahima Datla further stated that it was not clear when the company would start production, but it is also looking to introduce its own Covid-19 product.

Chugai Pharmaceutical announced positive results from its Phase III J-COVACTA clinical study for the humanised anti-human IL-6 receptor monoclonal antibody Actemra Intravenous Infusion to treat  patients with Covid-19 associated pneumonia. Actemra has not been approved by any health authorities, but Chugai will discuss filing with the Japanese health authority based on ongoing studies.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU